卵巢癌仍然是最致命的妇科恶性肿瘤。所有高级别浆液性卵巢癌 (HGSOC) 中的一半在双链 DNA 断裂修复方面存在同源重组缺陷 (HRD)，并且适合接受 PARP 抑制剂的维持治疗。虽然有大量关于从医学角度对患者进行治疗指导的文献，但 HRD 状态对手术前景的影响相对有限。在这篇综述中，考虑了具有 BRCA1/2 突变和/或 HRD 状态的晚期卵巢癌的临床和生物学特征，特别考虑了它们对手术治疗和内科手术顺序的影响。讨论了根据一线和复发情况下的分子检测结果修改手术适应症。版权所有 © 2024 作者。由 Elsevier B.V. 出版。保留所有权利。

Ovarian carcinoma remains the most lethal gynaecologic malignancy. Half of all high-grade serous ovarian cancers (HGSOCs) have a homologous recombination deficiency (HRD) with regard to the repair of double-strand DNA breaks and are candidate to receive maintenance treatment with PARP inhibitors. While a wealth of literature exists regarding the therapeutic guidance of patients from a medical standpoint, the influence of the HRD status on the surgical outlook has been comparatively limited. In this review, the clinical and biological features of advanced ovarian cancers with BRCA1/2 mutation and/or HRD status are considered with particular reference to their impact on the surgical management and on the medico-surgical sequence. The modification of the surgical indications according to the results of molecular testing in first-line and recurrent settings are discussed.Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.